FIELD: medicine.
SUBSTANCE: invention is related medicine and concerns applications of antibodies specifically recognising any prevailing variants of beta-amyloid peptide, Aβ40 and Aβ42, in preparation of a drug applied for prevention and-or treatment of Alzheimer's disease.
EFFECT: invention provides prevention of progression or reduction of symptoms, and/or decrease in amyloid deposition in an individual when administering an immunostimulating dose of peptide or specific antibody.
7 cl, 3 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ALZHEIMER'S DISEASE | 2009 |
|
RU2526155C2 |
| COMPOSITIONS OF PEPTIDE CONJUGATE AND METHODS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | 2006 |
|
RU2406529C2 |
| ACTIVE IMMUNISATION FOR CREATING SOLUBLE A-BETA ANTIBODIES | 2004 |
|
RU2390350C2 |
| METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH DEPOSIT OF AMYLOID PROTEINS (VERSIONS) | 2010 |
|
RU2533806C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
| AMYLOID CONJUGATE, ITS APPLICATIONS AND METHODS | 2017 |
|
RU2712750C1 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR ALZHEIMER'S DISEASE TREATMENT, ITS APPLICATION FOR RECEPTION OF THERAPEUTIC AGENTS, AND ALSO METHOD OF ALZHEIMER'S DISEASE TREATMENT BY MEANS OF GIVEN VECTOR | 2004 |
|
RU2335542C2 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
